FULCRUM THERAPEUTICS, INC. Contract Liability (Deferred Revenue)
FULCRUM THERAPEUTICS, INC. (FULC) had Contract Liability (Deferred Revenue) of $13.61 million as of 2020-09-30, per its 10-Q filed 2020-11-10.
Discontinued › Balance Sheet › Liabilities › Deferred Revenue, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2020-11-10
- 2020-09-30: Contract with Customer, Liability, Current $13.61M.
- 2020-06-30: Contract with Customer, Liability, Current $4.46M.
- 2020-03-31: Contract with Customer, Liability, Current $4.56M.
- 2019-12-31: Contract with Customer, Liability, Current $3.99M.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2020-09-30 | $13.61M 10-Q · filed 2020-11-10 |
| 2020-06-30 | $4.46M 10-Q · filed 2020-08-11 |
| 2020-03-31 | $4.56M 10-Q · filed 2020-05-13 |
| 2019-12-31 | $3.99M 10-Q · filed 2020-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |